Assessment of SF3B1 Expression as a Prognostic Marker for Neoadjuvant Chemotherapy Response in Stage III Triple-Negative Breast Cancer.

IF 1.2 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY

Reports of Biochemistry and Molecular Biology Pub Date : 2025-01-01 DOI:10.61186/rbmb.13.4.570

Desak Made Wihandani, Putu Anda Tusta Adiputra, Gede Wikania Wira Wiguna, Putu Gede Septiawan Saputra, Made Violin Weda Yani, Ida Ayu Widya Anjani, Wayan Ardyan Sudartha Putra, Gede Putu Supadmanaba

{"title":"Assessment of SF3B1 Expression as a Prognostic Marker for Neoadjuvant Chemotherapy Response in Stage III Triple-Negative Breast Cancer.","authors":"Desak Made Wihandani, Putu Anda Tusta Adiputra, Gede Wikania Wira Wiguna, Putu Gede Septiawan Saputra, Made Violin Weda Yani, Ida Ayu Widya Anjani, Wayan Ardyan Sudartha Putra, Gede Putu Supadmanaba","doi":"10.61186/rbmb.13.4.570","DOIUrl":null,"url":null,"abstract":"Background: SF3B1 is a splicing factor that plays a crucial role in cancer progression and is commonly found in various types of solid cancers. However, the reports regarding the clinical implications of SF3B1 in terms of therapy response, survival, and its relationship with patients' clinicopathological features are still limited. This study aimed to assess SF3B1 expression for neoadjuvant chemotherapy response in stage III triple-negative breast cancer.Methods: This case-control study was conducted at Prof. Dr. I.G.N.G. Ngoerah General Hospital from March to October 2021. Stage III TNBC breast cancer patients who received neoadjuvant chemotherapy were included. Variables assessed included SF3B1 expression, NAC response, and various histological and clinical parameters. Immunohistochemistry (IHC) for SF3B1 expression was performed using the avidin-biotin method. Data analysis involved univariate, bivariate (chi-square), and multivariate (logistic regression) methods using SPSS, with significance set at p ≤ 0.05.Results: Analysis showed that high Ki-67, tumor-infiltrating lymphocytes (TILs), and SF3B1 status significantly increased the risk of chemoresistance in TNBC breast cancer (OR=6.4, 95%CI=1.20-34.19, p-value=0.017; OR=4.8, 95%CI=1.05-21.75, p-value=0.031; OR=13.5, 95%CI=1.56-116.24, p-value=0.008, respectively) No significant relationships were found with age, grading, or menopausal status. Multivariate analysis confirmed these variables independently influenced chemoresistance, with aOR=14.4, 95%CI=1.80-115.73 for Ki-67 (p-value=0.012), aOR=6.7, 95%CI=1.12-40.46 for TIL (p-value=0.037), and aOR=13.714, 95%CI=1.56-116.24 for SF3B1 (p-value=0.018).Conclusions: High SF3B1 expression, alongside high Ki-67 and TIL levels, is potentially a prognostic marker for chemoresistance in stage III TNBC. These findings suggest that targeting SF3B1 could offer a novel therapeutic approach in TNBC patients.","PeriodicalId":45319,"journal":{"name":"Reports of Biochemistry and Molecular Biology","volume":"13 4","pages":"570-578"},"PeriodicalIF":1.2000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12367209/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reports of Biochemistry and Molecular Biology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.61186/rbmb.13.4.570","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: SF3B1 is a splicing factor that plays a crucial role in cancer progression and is commonly found in various types of solid cancers. However, the reports regarding the clinical implications of SF3B1 in terms of therapy response, survival, and its relationship with patients' clinicopathological features are still limited. This study aimed to assess SF3B1 expression for neoadjuvant chemotherapy response in stage III triple-negative breast cancer.

Methods: This case-control study was conducted at Prof. Dr. I.G.N.G. Ngoerah General Hospital from March to October 2021. Stage III TNBC breast cancer patients who received neoadjuvant chemotherapy were included. Variables assessed included SF3B1 expression, NAC response, and various histological and clinical parameters. Immunohistochemistry (IHC) for SF3B1 expression was performed using the avidin-biotin method. Data analysis involved univariate, bivariate (chi-square), and multivariate (logistic regression) methods using SPSS, with significance set at p ≤ 0.05.

Results: Analysis showed that high Ki-67, tumor-infiltrating lymphocytes (TILs), and SF3B1 status significantly increased the risk of chemoresistance in TNBC breast cancer (OR=6.4, 95%CI=1.20-34.19, p-value=0.017; OR=4.8, 95%CI=1.05-21.75, p-value=0.031; OR=13.5, 95%CI=1.56-116.24, p-value=0.008, respectively) No significant relationships were found with age, grading, or menopausal status. Multivariate analysis confirmed these variables independently influenced chemoresistance, with aOR=14.4, 95%CI=1.80-115.73 for Ki-67 (p-value=0.012), aOR=6.7, 95%CI=1.12-40.46 for TIL (p-value=0.037), and aOR=13.714, 95%CI=1.56-116.24 for SF3B1 (p-value=0.018).

Conclusions: High SF3B1 expression, alongside high Ki-67 and TIL levels, is potentially a prognostic marker for chemoresistance in stage III TNBC. These findings suggest that targeting SF3B1 could offer a novel therapeutic approach in TNBC patients.

查看原文本刊更多论文

SF3B1表达作为III期三阴性乳腺癌新辅助化疗反应的预后标志物的评估

背景：SF3B1是一种剪接因子，在癌症进展中起着至关重要的作用，常见于各种类型的实体癌。然而，关于SF3B1在治疗反应、生存以及与患者临床病理特征的关系方面的临床意义的报道仍然有限。本研究旨在评估SF3B1表达对III期三阴性乳腺癌新辅助化疗反应的影响。方法：本病例对照研究于2021年3月至10月在I.G.N.G. Ngoerah总医院进行。接受新辅助化疗的III期TNBC乳腺癌患者。评估的变量包括SF3B1表达、NAC反应以及各种组织学和临床参数。采用亲和素-生物素法免疫组化检测SF3B1的表达。数据分析采用SPSS单因素、双因素（卡方）和多因素（逻辑回归）方法，显著性设置为p≤0.05。结果：分析显示，高Ki-67、肿瘤浸润淋巴细胞（TILs）和SF3B1水平显著增加TNBC乳腺癌化疗耐药的风险（OR=6.4, 95%CI=1.20 ~ 34.19， p值=0.017；OR=4.8, 95%CI=1.05 ~ 21.75， p值=0.031；OR=13.5, 95%CI=1.56 ~ 116.24， p值=0.008），与年龄、分级、绝经状态无显著关系。多因素分析证实这些变量独立影响化疗耐药，Ki-67的aOR=14.4, 95%CI=1.80 ~ 115.73 (p值=0.012)，TIL的aOR=6.7, 95%CI=1.12 ~ 40.46 (p值=0.037)，SF3B1的aOR=13.714, 95%CI=1.56 ~ 116.24 （p值=0.018）。结论：SF3B1高表达、Ki-67和TIL高表达可能是III期TNBC化疗耐药的预后指标。这些发现表明，靶向SF3B1可能为TNBC患者提供一种新的治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Reports of Biochemistry and Molecular Biology BIOCHEMISTRY & MOLECULAR BIOLOGY-

CiteScore

2.80

自引率

23.50%

发文量

审稿时长

10 weeks

期刊介绍： The Reports of Biochemistry & Molecular Biology (RBMB) is the official journal of the Varastegan Institute for Medical Sciences and is dedicated to furthering international exchange of medical and biomedical science experience and opinion and a platform for worldwide dissemination. The RBMB is a medical journal that gives special emphasis to biochemical research and molecular biology studies. The Journal invites original and review articles, short communications, reports on experiments and clinical cases, and case reports containing new insights into any aspect of biochemistry and molecular biology that are not published or being considered for publication elsewhere. Publications are accepted in the form of reports of original research, brief communications, case reports, structured reviews, editorials, commentaries, views and perspectives, letters to authors, book reviews, resources, news, and event agenda.